4 completed, 4 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 3 Phase 1, 2 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Completed 2, Suspended 1 |
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Locally Advanced Gastric Adenocarcinoma: new trials by email Literature Review of Locally Advanced Gastric Adenocarcinoma trials Research Report on Locally Advanced Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer [18F]FAPI-74 PET/CT, [18F]-FAPI-74 - Locally Advanced Gastric Adenocarcinoma, STOMACH NEOPLASM | Phase 2 / Phase 3 | Recruiting | Leiden University Medical Center | 250 | 2025-07-03 | 2025-08-27 |
| Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer Single agent zimberelimab, Combination zimberelimab + domvanalimab - Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer | Phase 2 | Suspended | Royal Marsden NHS Foundation Trust | 50 | 2025-02-20 | 2026-08-21 |
| Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma Adebrelimab combined with SOX regimen, Placebo combined with SOX (S-1/oxaliplatin) regimen - Locally Advanced Gastric Adenocarcinoma | Phase 4 | Unknown | Yang Jianjun, PhD | 110 | 2023-12-30 | 2024-01-29 |
| Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy oral nutritional supplement - Locally Advanced Gastric Adenocarcinoma | Not applicable | Completed | Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital | 46 | 2023-02-01 | 2024-10-18 |
| Study of Comparing of With and Without Sequential Therapy of S-1 Docetaxel, Tegafur-Gimeracil-Oteracil - Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect | Phase 3 | Recruiting | Zhejiang University | 70 | 2023-01-28 | 2023-04-14 |
| Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma DNA panel and RNA Sequencing - Locally Advanced Gastric Adenocarcinoma, PD-1 | Completed | Xijing Hospital | 28 | 2022-07-18 | 2025-12-04 | |
| Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma Tislelizumab combined with Oxaliplatin and Capecitabine - Locally Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Xijing Hospital | 28 | 2022-07-18 | 2025-11-28 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma PD-1 antibody combined with FOLFIRINOX regimen, PD-1 antibody combined with SOX program - Locally Advanced Gastric Adenocarcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 124 | 2021-05-01 | 2021-06-01 |
| Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial Camrelizumab plus mFLOT regimen, R0 surgery - Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Fudan University | 40 | 2021-01-06 | 2025-03-12 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | Mayo Clinic | 36 | 2020-02-13 | 2026-03-18 |
Stomach Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Stomach Diseases (3) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · pembrolizumab (2) · Biopsy (1) · Capecitabine (1) · Clinical Protocols (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Dietary Supplements (1) · Docetaxel (1) · Immunoglobulin G (1) · Oxaliplatin (1) · Paclitaxel (1) · Ramucirumab (1) · S 1 (combination) (1)
Mayo Clinic (2) · Xijing Hospital (2) · Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital (1) · Fudan University (1) · Leiden University Medical Center (1) · Northwestern University (1) · Royal Marsden NHS Foundation Trust (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Yang Jianjun, PhD (1) · Zhejiang University (1)
China (6) · United States (3) · Netherlands (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Gladys Rodriguez, MD (1) · Mojun Zhu, M.D. (1) · Naureen Starling (1) · Yanyan Lou, MD, PhD (1)
P30CA060553 (1)